|Assessment Status||Rapid Review Complete|
|Drug||Trientine Tetrahydrochloride (TETA 4HCL)|
|Indication||For the treatment of Wilson’s disease in adults and children ≥ five years intolerant to D-penicillamine therapy.|
|Rapid review commissioned||19/08/2019|
|Rapid review completed||09/10/2019|
|Rapid review outcome||A full HTA is not recommended.The NCPE recommends that trientine tetrahydrochloride (TETA 4HCl) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations, March 2020.